More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
The FDA approves another generic version of Abilify; drug price increases driving profit growth; Spark plans to submit eye-drug to the FDA in 2016
The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation
Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals
A panel composed of physicians and medical researchers expressed caution in prescribing PCSK9 inhibitors for off-label uses.
Clinton expecting to discuss drug prices; Turing criticized for raising the price of infectious-disease drug; online game helps patients reduce blood pressure
Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target
Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines
CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration
The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.
The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.
Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.
A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.
Transitional pass-through reimbursement status clears way for commercialization.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media